Immunotherapy in Eosinophilic Granulomatosis with Polyangiitis: A New Step Forward?

Xavier Puéchal*

National Referral Center for Rare Systemic Autoimmune Diseases, Necrotizing Vasculitides, Department of Internal Medicine, Université Paris Descartes

Hôpital Cochin, Assistance Publique – Hôpitaux de Paris 27, rue du faubourg Saint Jacques, 75014 Paris, France

Corresponding author: Xavier Puéchal, National Referral Center for Rare Systemic Autoimmune Diseases, Necrotizing Vasculitides, Department of Internal Medicine, Université Paris Descartes and INSERM U1016, Cochin Institute, Paris, France. Tel: 33 1 58 41 32 41; Fax: 33 1 58 41 29 68; E-mail: xavier.puechal@aphp.fr

Received date: March 25, 2016; Accepted date: March 28, 2016; Published date: March 31, 2016

Copyright: © 2016 Puéchal X. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) [1]. EGPA has distinct features, namely asthma, common rhino-sinusal involvement, hyper eosinophilia, tissue infiltration with eosinophils and necrotizing granulomatosis vasculitis [2-4].

Conventional immunosuppressive therapy and glucocorticoids have been GPA and MPA standard of care for remission induction and maintenance for four decades. This regimen has transformed the outcome from death to a strong likelihood of disease control and temporary remission. However, most patients have recurrent relapses that lead to damage and require repeated treatment. Cumulative side effects of immunosuppressive agents and glucocorticoids thus remain major causes of long-term morbidity, damage and death.

The development of therapeutic immunomodulation in systemic autoimmune diseases has shed new light on these complex diseases [5,6]. Rituximab, an anti-CD20 monoclonal antibody that depletes B-cells in peripheral blood, has been shown to be not inferior to cyclophosphamide to induce remission in GPA and MPA patients, with an acceptable safety profile, leading to its registration by the EMA and FDA as drug remission-induction therapy in these patients [7-9]. In addition the MAINRITSAN trial, conducted by the French Vasculitis Study Group, demonstrated that pre-emptive low dose rituximab given every 6 months for 18 months was significantly more effective than azathioprine standard of care to maintain remission in GPA and MPA, with a similar profile of tolerance [10]. Such therapeutic immunomodulation has changed the standard of care for maintenance therapy in these vasculitides.

Patients with EGPA were excluded from these pivotal trials because this vasculitis is rarer and positive ANCA tests are less frequent than in other ANCA-associated vasculitides. In a long-term analysis of randomized trials of 118 EGPA patients, we have reported that only 29% of patients achieved long-term remission and that relapses occurred in more than 40% of patients, leading to high cumulative morbidity and damage [3]. Moreover, most of these patients cannot be weaned of corticosteroids due to asthma and rhino-sinusal ongoing manifestations, even after vasculitis remission. Their long-term outcome remains to be improved.

Progress has been made in the assessment of EGPA vasculitis activity and of rhino-sinusal manifestations. The EULAR expert recommendations for definition of remission include a prednisone dose \( \leq 7.5 \text{mg/day} \) [11]. It is now recognized in EGPA that ear, nose and throat (ENT) manifestations and/or asthma flares may not necessarily reflect vasculitis activity [2,3]. The EGPA Task Force recently proposed that the definition of remission in EGPA do not include the control of asthma and/or ENT manifestations [12]. These symptoms should be monitored separately and results should be given beside the evaluation of the vasculitis activity.

EGPA is classically considered a TH2-mediated disease with an activated and skewed T-cell balance [13]. EGPA patients T cells can produce high levels of TH2-associated cytokines such as IL-4 and IL-13 [14]. IL-5 is also up-regulated in active EGPA and is particularly essential for eosinophil activation, maturation and survival. However, the clinical phenotype cannot be explained by an isolated exaggerated TH2 response [4]. Th1 and Th17 cells are also implicated and secrete high amounts of IL-17A in the late phases of the disease [4,14]. Moreover, several lines of evidence also point to a role of B lymphocytes and humoral responses as further contributing to EGPA pathogenesis. Increase in the levels of activated and memory B cells have been found in active EGPA [15]. Myeloperoxidase (MPO)-pANCA are present in 40% of untreated patients [2]. Patients with EGPA flares often had increased levels of total serum IgE and IgE-containing immune complexes [16], initially supported the hypothesis that EGPA might be an allergy-induced, immune-complex vasculitis. Elevated serum IgG4 have also been common features and the switch towards IgG4 production is related to the inflammatory milieu conditioning B-cell maturation, and particularly to the presence of TH2 cytokines such as IL4, IL5 and IL13 [17].

Furthermore, recent case reports and small retrospective series [18-25] have indicated that rituximab may also be an effective remission induction agent in refractory or relapsing EGPA. A review of published series of rituximab for EGPA patients is shown in Table 1. A total of 73 EGPA patients who had received rituximab, mainly for refractory or relapsing disease, have been compiled in a recent analysis [26]. Efficacy of rituximab therapy was significant in the vast majority of cases and in a wide variety of disease manifestations. The largest series to date has reported 41 EGPA patients, who received rituximab in four expert vasculitis centers, mostly for refractory or relapsing disease [24]. Patients with positive ANCA testing were significantly more likely to achieve remission at 12 months: 80% (12/15) who were ANCA-positive versus 36% (8/21) who were ANCA-negative. In contrast, Thiel et al. have reported in 9 patients, that rituximab appeared to be an efficient and safe treatment for both ANCA-positive and ANCA-negative patients [23], as also mentioned by Novikov et al [25]. Largest prospective studies will have to clarify this issue.
In the study reported by Muhammad et al., type and rate of response did not differ between the patients treated with rituximab 375 mg/m² for 4 weeks or with two doses of 1g given two weeks apart [24], as already shown in a retrospective study of patients with ANCA-associated vasculitis, of whom 5 had EGPA [27]. Apart infectious complications which may be severe in these immunocompromised patients already receiving glucocorticoids, other safety issues included infusion reactions in two patients requiring intubation due to worsening of asthma in one [24]. Severe bronchospasm has already been reported during the first 15 minutes of rituximab infusions in two EGPA patients [20]. In addition, very few patients also received rituximab as maintenance therapy in EGPA to prevent relapses. In a study, preemptive retreatment with rituximab in three patients, combined with standard maintenance immunosuppressant resulted in a sustained response with a median follow-up of 3 years [23].

The mechanisms by which an anti-CD20 therapy might be efficient in EGPA remain unclear. It has been hypothesized that activated B cells may contribute to mechanisms of tissue injury as antigen-presenting cells, regulating the development of effector T cells by expressing costimulatory molecules, and as precursors to plasma cells, giving rise

<table>
<thead>
<tr>
<th>Authors [reference]</th>
<th>Year</th>
<th>Design</th>
<th>Number</th>
<th>ANCA</th>
<th>RTX dosing</th>
<th>Outcome</th>
<th>Severe adverse events</th>
<th>Median duration follow-up (months)</th>
<th>Mean prednisone dose decrease (mg/day)</th>
<th>RTX retreatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koukoulaki [18]</td>
<td>2006</td>
<td>Retrospective</td>
<td>2</td>
<td>None</td>
<td>None (N=1); NA (N=1) 375 mg/m² weekly x 4 (N=1)</td>
<td>Remission: 2/2</td>
<td>Respiratory tract infection (N=1)</td>
<td>16.5</td>
<td>12.5 =&gt; 4.5</td>
<td>One patient required repeated RTX infusions at M7 and M16 due to nasal and asthma flare with eosinophilia</td>
</tr>
<tr>
<td>Pepper [19]</td>
<td>2008</td>
<td>Retrospective</td>
<td>2</td>
<td>Anti-MPO</td>
<td>Anti-MPO (N=1); Anti-PR3 (N=1) 1g, 2 weeks apart (N=1); 375 mg/m² weekly x 4 (N=1)</td>
<td>Remission: 2/2</td>
<td>None reported</td>
<td>6</td>
<td>NA</td>
<td>None</td>
</tr>
<tr>
<td>Boudouyre [20]</td>
<td>2009</td>
<td>Retrospective</td>
<td>2</td>
<td>None</td>
<td>375 mg/m² (N=2)</td>
<td>NA</td>
<td>Severe bronchospasm during infusion (N=2)</td>
<td>NA</td>
<td>NA</td>
<td>RTX was withdrawn</td>
</tr>
<tr>
<td>Donvik [21]</td>
<td>2011</td>
<td>Retrospective</td>
<td>2</td>
<td>None</td>
<td>1g, 2 weeks apart (N=2)</td>
<td>Remission: 2/2</td>
<td>None reported</td>
<td>12.5</td>
<td>NA</td>
<td>Preemptive RTX retreatment for 6 and 18 months, for one patient each</td>
</tr>
<tr>
<td>Cartin-Ceba [22]</td>
<td>2011</td>
<td>Prospective o</td>
<td>3</td>
<td>Anti-MPO</td>
<td>Anti-MPO (N=3) 375 mg/m² weekly x 4 (N=3)</td>
<td>Remission M12: 3/3</td>
<td>None reported</td>
<td>12</td>
<td>50 =&gt; 3.3</td>
<td>One patient had successful repeated RTX infusions at M6 for a vasculitis relapse</td>
</tr>
<tr>
<td>Thiel [23]</td>
<td>2013</td>
<td>Retrospective</td>
<td>9</td>
<td>Anti-MPO</td>
<td>Anti-MPO (N=5) 1g, 2 weeks apart (N=9)</td>
<td>Remission M9: 6/9</td>
<td>None related to RTX</td>
<td>9</td>
<td>15 =&gt; 7.5</td>
<td>Preemptive RTX retreatment in 3 patients resulted in a sustained response with a median follow-up of 3 years</td>
</tr>
<tr>
<td>Mohammad [24]</td>
<td>2016</td>
<td>Retrospective</td>
<td>41</td>
<td>Anti-MPO</td>
<td>Anti-MPO (N=9); Anti-PR3 (N=4) 375 mg/m² weekly x 4 (N=10); 1g, 2 weeks apart (N=30); 0.8g, 2 weeks apart (N=1)</td>
<td>Remission M12: ANCA+; 80%; ANCA-: 38%</td>
<td>10 in 21 patients after a total of 79 RTX courses within one year: infection (N=6); infection reaction (N=2); other (N=2)</td>
<td>12</td>
<td>15 =&gt; 8</td>
<td>Relapse in 4 patients at M12; Preemptive RTX retreatment in 22 patients</td>
</tr>
<tr>
<td>Novikov [25]</td>
<td>2016</td>
<td>Retrospective</td>
<td>6</td>
<td>Anti-MPO</td>
<td>Anti-MPO (N=3); Anti-PR3 (N=1) 0.5 g weekly x 4 (N=3); 1g, 2 weeks apart (N=1); 0.5g, 2 weeks apart (N=2)</td>
<td>Remission M6: 4/6</td>
<td>Severe bronchospasm during infusion (N=1); infection (N=2)</td>
<td>10</td>
<td>35 =&gt; 8.75</td>
<td>Preemptive RTX retreatment in one patient resulted in a sustained response with a median follow-up of 3.5 years</td>
</tr>
</tbody>
</table>

Table 1: Rituximab for treatment of eosinophilic granulomatosis with polyangiitis.
EGPA [33,34]. Two pilot studies with mepolizumab in EGPA have corticosteroids, particularly forms characterized by predominant standard of care therapy including background corticosteroid therapy treatment.

damage and quality of life.

rationale for further studies.

EGPA for safer therapy that leads to sustained remission, in order to the absence of further conventional immunosuppressants [33,34]. A been treated with omalizumab with large randomized, double-blind, phase III study is currently confirmed efficacy 
alveolar hemorrhage) and the presence of anti-MPO ANCA [28].

As now accepted with leukotriene antagonists, it is likely that immunomodulation with rituximab may be an effective maintenance treatment.

Mepolizumab, a humanized monoclonal antibody against IL-5, has also generated promising results in eosinophilic asthma [29-32] and EGPA [33,34]. Two pilot studies with mepolizumab in EGPA have reported a corticosteroid sparing effect and remission maintenance in the absence of further conventional immunosuppressants [33,34]. A large randomized, double-blind, phase III study is currently investigating the efficacy and safety of mepolizumab compared with placebo in subjects with relapsing or refractory EGPA receiving standard of care therapy including background corticosteroid therapy with or without immunosuppressive therapy (MIRRA, ClinicalTrials.gov Identifier: NCT02020889).

Other therapeutic immunomodulation are being evaluated in EGPA. The introduction of anti-IgE therapy for asthma inaugurated the era of biological therapies and has been shown to be useful for patients with allergic severe asthma [35,36]. EGPA patients have also been treated with omalizumab with conflicting results [37,38], some patients presenting vasculitis onset after omalizumab therapy [39,40]. As now accepted with leukotriene antagonists, it is likely that omalizumab may have unmasked a preexisting vasculitis in some cases but additional data are necessary before concluding that omalizumab has no role in these complications.

In conclusion, there remains a major unmet need in patients with EGPA for safer therapy that leads to sustained remission, in order to reduce cumulative damage, morbidity and drug toxicity. The utility of rituximab and mepolizumab for the treatment of EGPA remains unproven, but initial reports of their efficacy/safety have provided a rationale for further studies. The ongoing randomized controlled trials with rituximab and mepolizumab are a new step forward in EGPA both as an induction and maintenance therapy. They will also have to evaluate these immunomodulating agents in terms of steroid sparing, damage and quality of life.

References


